Sydney, Australia, April 27th, 2018 – MEDISCA Australia, a leader in the compounding pharmaceutical industry, is pleased to announce that they had a successful cGMP inspection by the Therapeutic Goods Administration (TGA). The TGA issued an A1 compliant rating of the facility. This is a demonstration of its excellent Quality Management System and continuous efforts in meeting regulatory requirements.
MEDISCA Australia strives to continuously increase the standard of quality of its products and is dedicated to achieving the highest level of compliance. This achievement is yet another example of MEDISCA Australia staying true to its vision to be the global standard bearer for quality, innovation and service in the compounding industry.
MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Through its global partners, LP3 Network and MEDISCA Network, MEDISCA is committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine by offering educational trainings, products, and support. Founded in 1989, the company has locations in Canada, the United States and Australia, optimizing its service to the international market. For more information about MEDISCA, please visit www.medisca.com and follow us on Twitter at @medisca.